Accession Number : AD1013856


Title :   Bacillus Collagen Like Protein of Anthracis: Immunological and Functional Analyses


Descriptive Note : Technical Report


Corporate Author : UNIFORMED SERVICES UNIV OF THE HEALTH SCIENCES BETHESDA MD BETHESDA United States


Personal Author(s) : Brahmbhatt,Trupti N


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1013856.pdf


Report Date : 21 Sep 2007


Pagination or Media Count : 149


Abstract : Interest in the development of an improved anthrax vaccine has increased since the 2001 bioterrorist event that involved the public dispersal of Bacillus anthracis spores through the United States postal system. The currently licensed anthrax vaccine adsorbed (AVA) is a crude extract in which the primary protective immunogen is the toxin binding component of the anthrax toxins, called protective antigen (PA); this antigen is given to elicit toxin-neutralizing antibodies in the recipient. Unfortunately, AVA has several drawbacks not the least of which are that it is administered as a six dose series over an extended period and that painful local reactions to the vaccine are commonly reported. Moreover, AVA may be less than optimally effective against the most lethal form of the disease, inhalational anthrax. Therefore, the first goal of this study was to explore the use of a B. anthracis spore surface antigen as a means of increasing protection afforded by a Protective Antigen (PA) - based vaccine.


Descriptors :   ANTHRAX , Bacillus anthracis , antibacterial agents , vaccines


Subject Categories : Medicine and Medical Research
      Microbiology


Distribution Statement : APPROVED FOR PUBLIC RELEASE